Acute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno study group

Blood

Volumn 123, Issue 1, 2014, Pages 70-77

  Buitenkamp, Trudy D ^a   Izraeli, Shai ^b   Zimmermann, Martin ^c   Forestier, Erik ^d   Heerema, Nyla A ^e   Van Den Heuvel Eibrink, Marry M ^a   Pieters, Rob ^a,f   Korbijn, Carin M ^f   Silverman, Lewis B ^g   Schmiegelow, Kjeld ^h   Liang, Der Cheng ⁱ   Horibe, Keizo ^j   Arico, Maurizio ^k   Biondi, Andrea ^l   Basso, Giuseppe ^m   Rabin, Karin R ⁿ   Schrappe, Martin ^o   Cario, Gunnar ^o   Mann, Georg ^p   Morak, Maria ^p   Panzer Grümayer, Renate ^p   Mondelaers, Veerle ^q   Lammens, Tim ^q   Cav́, Hèléne ^r   Stark, Batia ^s   Ganmore, Ithamar ^b   Moorman, Anthony V ^t   Vora, Ajay ^u   Hunger, Stephen P ^v   Pui, Ching Hon ^w   Mullighan, Charles G ^x   Manabe, Atsushi ^w   Escherich, Gabriele ^y   Kowalczyk, Jerzy R ^z   Whitlock, James A ^aa   Zwaan, C Michel ^a   more..

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b SHEBA MEDICAL CENTER   (Israel)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UMEÅ UNIVERSITY   (Sweden)

^e OHIO STATE UNIVERSITY   (United States)

^f DCOG Dutch Childhood Oncology Group   (Netherlands)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

ⁱ MACKAY MEMORIAL HOSPITAL   (Taiwan)

^j NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^k UNIVERSITY OF FLORENCE   (Italy)

^l UNIVERSITY OF MILANO BICOCCA   (Italy)

^m UNIVERSITY OF PADOVA   (Italy)

ⁿ BAYLOR COLLEGE OF MEDICINE   (United States)

^o UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^p MEDICAL UNIVERSITY OF VIENNA   (Austria)

^q GHENT UNIVERSITY HOSPITAL   (Belgium)

^r HÔPITAL ROBERT DEBRÉ   (France)

^s SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^t NEWCASTLE UNIVERSITY   (United Kingdom)

^u SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^v Nutrition Obesity Research Center at the University of Colorado   (United States)

^w Department of Oncology ^*  (Japan)

^x ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^y UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^z MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^aa HOSPITAL FOR SICK CHILDREN   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 10; CHROMOSOME 4; CHROMOSOME ANALYSIS; DOWN SYNDROME; EVENT FREE SURVIVAL; FEMALE; GENE REARRANGEMENT; HUMAN; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SECOND CANCER; TREATMENT OUTCOME;

EID: 84891823402     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-509463     Document Type: Article

References (55)

1. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355(9199): 165-169. (Pubitemid 30068214)
2. Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008; 111(3):1575-1583. (Pubitemid 351213448)
3. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115(5):1006-1017.
4. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitorand Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11): 1243-1246.
5. Dördelmann M, Schrappe M, Reiter A, et al Berlin-Frankfurt- Münster Group. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Leukemia. 1998;12(5):645-651. (Pubitemid 28220815)
6. Arico M, Ziino O, Valsecchi MG, et al Italian Association of Pediatric Hematology and Oncology (AIEOP). Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Cancer. 2008;113(3): 515-521.
7. Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM; Medical Research Council Working Party on Childhood Leukaemia. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol. 2002;117(2):306-314. (Pubitemid 34451145)
8. Zeller B, Gustafsson G, Forestier E, et al Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005;128(6):797-804. (Pubitemid 40444872)
9. Shah N, Al-Ahmari A, Al-Yamani A, Dupuis L, Stephens D, Hitzler J. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer. 2009;52(1):14-19.
10. Bassal M, La MK, Whitlock JA, et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005;44(1):21-28. (Pubitemid 39602561)
11. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO; Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129(6): 734-745. (Pubitemid 40904523)
12. Baillargeon J, Langevin AM, Mullins J, et al. Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2005;45(7):960-963. (Pubitemid 41552166)
13. Belgaumi AF, Al-Bakrah M, Al-Mahr M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer. 2003; 97(11):2898-2903. (Pubitemid 36605160)
14. Cetin M, Yetgin S, Kara A, et al. Hyperglycemia, ketoacidosis and other complications of Lasparaginase in children with acute lymphoblastic leukemia. J Med. 1994;25(3-4):219-229. (Pubitemid 24282287)
15. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev. 2002;16(4):225-243. (Pubitemid 35230786)
16. Buitenkamp TD, Matĥ ot RA, de Haas V, Pieters R, Zwaan CM. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica. 2010; 95(7):1106-1113.
17. Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS. Challenging issues in pediatric oncology. Not Rev Clin Oncol. 2011;8(9):540-549.
18. Maloney KW, Carroll WL, Carroll AJ, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood. 2010;116(7):1045-1050.
19. Whitlock JA, Sather HN, Gaynon P, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005; 106(13):4043-4049. (Pubitemid 41775907)
20. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372(9648):1484-1492.
21. Ensor HM, Schwab C, Russell LJ, et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011;117(7):2129-2136.
22. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312-5321.
23. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688-2698.
24. Blink M, Buitenkamp TD, van den Heuvel-Eibrink MM, et al. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011;25(8):1365-1368.
25. Gaikwad A, Rye CL, Devidas M, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009;144(6):930-932.
26. Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2010;107(1):252-257.
27. Buitenkamp TD, Pieters R, Gallimore NE, et al. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia. 2012;26(10):2204-2211.
28. Biondi A, Baruchel A, Hunger S, et al. The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009. Leukemia. 2009;23(12):2318-2324.
29. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010; 24(2):309-319.
30. Möricke A, Zimmermann M, Reiter A, et al. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265-284.
31. Gaynon PS, Angiolillo AL, Carroll WL, et al Children's Oncology Group. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia. 2010;24(2): 285-297.
32. Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001.Leukemia. 2010;24(2):406-418.
33. Pui CH, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010; 24(2):371-382.
34. Schmiegelow K, Forestier E, Hellebostad M, et al Nordic Society of Paediatric Haematology and Oncology. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2): 345-354.
35. Stark B, Nirel R, Avrahami G, et al. Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia. 2010;24(2):419-424.
36. Tsuchida M, Ohara A, Manabe A, et al Tokyo Children's Cancer Study Group. Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984- 1999. Leukemia. 2010;24(2):383-396.
37. Vilmer E, Suciu S, Ferster A, et al Children Leukemia Cooperative Group. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia. 2000;14(12): 2257-2266. (Pubitemid 32042266)
38. Liang DC, Yang CP, Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2): 397-405.
39. Shaffer LG, Tommerup N. ISCN 2005: An International System for Human Cytogenetic Nomenclature (2005). Recommendations of the International Standing Committee of Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 2005.
40. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18-24. (Pubitemid 26019992)
41. Harris MB, Shuster JJ, Carroll A, et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood. 1992; 79(12):3316-3324.
42. Lundin C, Heldrup J, Ahlgren T, Olofsson T, Johansson B. B-cell precursor t(8;14)(q11;q32)- positive acute lymphoblastic leukemia in children is strongly associated with Down syndrome or with a concomitant Philadelphia chromosome. Eur J Haematol. 2009;82(1):46-53.
43. Messinger YH, Higgins RR, Devidas M, Hunger SP, Carroll AJ, Heerema NA. Pediatric acute lymphoblastic leukemia with a t(8;14)(q11.2;q32): B-cell disease with a high proportion of Down syndrome: a Children's Oncology Group study. Cancer Genet. 2012;205(9):453-458.
44. Pui CH, Raimondi SC, Borowitz MJ, et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol. 1993;11(7): 1361-1367. (Pubitemid 23199142)
45. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOPBFM ALL 2000 study. Blood. 2010;115(16): 3206-3214.
46. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731-1738. (Pubitemid 28534955)
47. Goto H, Inukai T, Inoue H, et al. Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group. Int J Hematol. 2011;93(2):192-198.
48. Bohnstedt C, Levinsen M, Rosthøj S, et al Nordic Society of Pediatric Hematology and Oncology (NOPHO). Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia. Leukemia. 2013;27(4):866-870.
49. Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002;99(1): 245-251.
50. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2001;2(7):429-436. (Pubitemid 33585947)
51. Cario G, Zimmermann M, Romey R, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood. 2010;115(26): 5393-5397.
52. Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012;120(17):3510-3518.
53. Meyr F, Escherich G, Mann G, et al. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. Br J Haematol. 2013;162(1):98-106.
54. Cetiner S, Demirhan O, Inal TC, Tastemir D, Sertdemir Y. Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome. Int J Immunogenet. 2010;37(4):233-237.
55. Chaushu S, Chaushu G, Zigmond M, et al. Age-dependent deficiency in saliva and salivary antibodies secretion in Down's syndrome. Arch Oral Biol. 2007;52(11): 1088-1096. (Pubitemid 47503120)